EXenatide Study of Cardiovascular Event Lowering
DTU Director discusses EXSCEL
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.
ACP Journal Club review of EXSCEL
The ACP Journal Club has identified EXCSEL as an original study that warrants immediate attention by physicians attempting to keep pace with important advances in internal medicine.
[Click here to see review